Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - idarubicin hydrochloride - powder for solution for injection - idarubicin hydrochloride 5 mg - antineoplastic agents

Canada - English - Health Canada

adria laboratories of canada ltd. - idarubicin hydrochloride - powder for solution - 10mg - idarubicin hydrochloride 10mg - antineoplastic agents

Canada - English - Health Canada

adria laboratories of canada ltd. - idarubicin hydrochloride - powder for solution - 5mg - idarubicin hydrochloride 5mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - doxorubicin hydrochloride, quantity: 10 mg - injection, concentrated - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - doxorubicin has been used successfully to produce regression in neoplastic conditions such as: acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc. the main antitumour activities are listed in table 1 of the product information. doxorubicin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder. (tis, t1, t2).

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - doxorubicin has been used successfully to produce regression in neoplastic conditions such as: acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc. the main antitumour activities are listed in table 1 of the product information. doxorubicin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder. (tis, t1, t2).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium chloride - adriamycin has been used successfully to produce regression in neoplastic conditions such as: acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc. the main antitumour activities are listed in table 1 of the product information. adriamycin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder. (tis, t1, t2).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - doxorubicin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - doxorubicin hydrochloride -

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - idarubicin hcl - injection - 10 mg/10 ml - idarubicin hcl 10 mg/10 ml

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - idarubicin hcl - injection - 5 mg/5 ml - idarubicin hcl 5 mg/5 ml